论文信息 - Ezetimibe, oxidized low density lipoprotein, Lp (a), and dyslipidemia. - 字舞流文

Ezetimibe, oxidized low density lipoprotein, Lp (a), and dyslipidemia.

increased cholesterol absorption.

Francisco A H Fonseca | M. C. Izar | H. Bianco | H. Fonseca

[1] T. Nozue,et al. Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. , 2010, Journal of atherosclerosis and thrombosis.

[2] Børge G Nordestgaard,et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial , 2009, The Lancet.

[3] R. Fagard,et al. Influence of exercise at lower and higher intensity on blood pressure and cardiovascular risk factors at older age , 2009, Journal of hypertension.

[4] A. DeMaria,et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. , 2008, Journal of the American College of Cardiology.

[5] T. Strandberg,et al. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis , 2006, Current medical research and opinion.